GoBroad Healthcare Group

Founded in 2017, GoBroad Healthcare Group (GHG) focuses on clinical treatment, clinical research, reference laboratories and information technology. GHG has joined hands with a group of top-notch medical experts with rich clinical experience and scientific research backgrounds to create a unique “Academic Research Organization (ARO)”. Our organizational strategy is to build an innovative medical ecosystem of “clinical discovery-basic research-industrial transformation-clinical application” and improve the efficiency and quality of development in the biomedicine industry. A research-oriented hospital is an important carrier of the ARO mode, and GoBroad Healthcare Group is a pioneer of the research-oriented hospital mode in China. The GHG currently operates seven hospitals in Beijing, Shanghai and Guangzhou, with a combined open bed capacity of nearly 1500 beds. The GHG focuses on innovative and research-active specialties such as solid tumors, hematological diseases and brain science. We are a national leader in a number of cancer therapies, such as adoptive cell therapy, immunotherapy and targeted therapy. In particular, our team of experts has extensive experience in chimeric antigen receptor T cell immunotherapy, also known as CAR-T Therapy. In addition, we are equipped with a professional healthcare multidisciplinary team to provide comprehensive and personalized integrated medical care in pursuit of more accurate diagnosis and more humanistic patient services. With the medical mission of treating severe diseases that have proved to be difficult to treat, GHG has brought more treatment options and hope to the vast number of patients with severe diseases that are difficult to treat. With the scientific research mission of promoting medical innovation, GHG has served hundreds of innovative pharmaceutical companies in a large number of innovative drug clinical trials.